Suppr超能文献

关于脊柱裂成人预防尿路感染的系统评价与实践政策声明。

Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida.

作者信息

Tradewell Michael, Pariser Joseph J, Nimeh Tony, Elliott Sean P

机构信息

Department of Urology, University of Minnesota, Minneapolis, MN, USA.

出版信息

Transl Androl Urol. 2018 May;7(Suppl 2):S205-S219. doi: 10.21037/tau.2018.04.21.

Abstract

Urinary tract infection (UTI) is a source of morbidity and healthcare costs in adults with spina bifida (ASB). UTI prevention strategies are often recommended, but the evidence of various approaches remains unclear. We performed a systematic review to inform a best practice policy statement for UTI prevention in ASB. On behalf of the Neurogenic Bladder Research Group (NBRG.org), we developed an a priori protocol and searched the published English literature for 30 outcomes questions addressing UTI prevention in ASB. The questions spanned the categories of antibiotics, oral supplements, bladder management factors and social support. Where there was little literature in ASB, we included literature from similar populations with neurogenic bladder (NB). Data was abstracted and then reviewed with recommendations made by consensus of all authors. Level of Evidence (LoE) and Grade of Recommendation (GoR) were according to the Oxford grading system. Of 6,433 articles identified by our search, we included 99 publications. There was sufficient evidence to support use of the following: saline bladder irrigation (LoE 1, GoR B), gentamicin bladder instillation (LoE 3, GoR C), single-use intermittent catheterization (IC) (LoE 2, GoR B), hydrophilic catheters for IC (LoE 2, GoR C), intradetrusor onabotulinumtoxinA injection (LoE 3, GoR C), hyaluronic acid (HA) instillation (LoE 1, GoR B), and care coordination (LoE 3, GoR C). There was sufficient evidence to recommend against use of the following: sterile IC (LoE 1, GoR B), oral antibiotic prophylaxis (LoE 2, GoR B), treatment of asymptomatic bacteriuria (LoE 2, GoR B), cranberry (LoE 2, GoR B), methenamine salts (LoE 1, GoR B), and ascorbic acid (LoE1, GoR B). There was insufficient evidence to make a recommendation for other outcomes. Overall, there are few studies in UTI prevention in the specific population of ASB. Research in populations similar to ASB helps to guide recommendations for UTI prevention in the challenging patient group of ASB. Future studies in UTI prevention specific to ASB are needed and should focus on areas shown to be of benefit in similar populations.

摘要

尿路感染(UTI)是脊柱裂成年患者(ASB)发病和医疗费用的一个来源。通常推荐采取UTI预防策略,但各种方法的证据仍不明确。我们进行了一项系统综述,以制定ASB患者UTI预防的最佳实践政策声明。代表神经源性膀胱研究小组(NBRG.org),我们制定了一个先验方案,并在已发表的英文文献中搜索了30个关于ASB患者UTI预防的结局问题。这些问题涵盖抗生素、口服补充剂、膀胱管理因素和社会支持等类别。在ASB相关文献较少的情况下,我们纳入了来自神经源性膀胱(NB)相似人群的文献。提取数据后,由所有作者达成共识进行评审并给出建议。证据水平(LoE)和推荐等级(GoR)根据牛津分级系统确定。在我们搜索到的6433篇文章中,我们纳入了99篇出版物。有充分证据支持使用以下方法:膀胱盐水灌注(证据水平1,推荐等级B)、庆大霉素膀胱灌注(证据水平3,推荐等级C)、一次性间歇性导尿(IC)(证据水平2,推荐等级B)、用于IC的亲水导尿管(证据水平2,推荐等级C)、膀胱内注射A型肉毒毒素(证据水平3,推荐等级C)、透明质酸(HA)灌注(证据水平1,推荐等级B)以及护理协调(证据水平3,推荐等级C)。有充分证据反对使用以下方法:无菌IC(证据水平1,推荐等级B)、口服抗生素预防(证据水平2,推荐等级B)、无症状菌尿的治疗(证据水平2,推荐等级B)、蔓越莓(证据水平2,推荐等级B)、乌洛托品盐(证据水平1,推荐等级B)以及抗坏血酸(证据水平1,推荐等级B)。对于其他结局,没有足够证据给出推荐。总体而言,针对ASB这一特定人群的UTI预防研究较少。对与ASB相似人群的研究有助于为ASB这一具有挑战性的患者群体的UTI预防提供指导建议。未来需要开展针对ASB患者UTI预防的具体研究,并且应聚焦于在相似人群中已显示有益的领域。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验